Teva Advances Pain Management Strategy with Labrys Biologics Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 8 (Table of Contents)
Published: 2 Aug-2014
DOI: 10.3833/pdr.v2014.i8.2047 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Teva Pharmaceutical Industries has acquired Labrys Biologics for US$200 M upfront plus up to US$625 M in pre-launch milestone payments...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS